146 pharmaceutical companies published annual reports, 85% of them earned!

[China Pharmaceutical network industry trends] in 2017, the performance of China's pharmaceutical industry was generally good According to the data released by the Bureau of statistics on the operation of the pharmaceutical industry in the new year, in 2017, the main business income of the national pharmaceutical manufacturing industry reached 281.85 billion yuan, an increase of 12.50% year on year In 2018, the pharmaceutical industry continued to maintain moderate growth According to the operation data of the pharmaceutical industry in February 2018, the main business income was 402.93 billion yuan, up 18.30% year on year; the total profit was 331.41 billion yuan, up 17.80 year on year; the total profit in February 2018 was 512 billion yuan, up 37.3% year on year; the landscape of the pharmaceutical manufacturing industry continued to recover At the same time, according to the new data of the State Administration, in the near future, the overall production situation of the pharmaceutical industry is also good due to the impact of the price rise of upstream raw materials In the quarter of 2018, most of the domestic pharmaceutical industry released annual reports As of April 1, according to the statistics of tonghuashun and other websites, 146 enterprises have issued annual reports, and the overall performance growth rate has increased, about 15% higher than that of 2016 Among these 146 enterprises, some are happy and others are sad According to the statistics of cypress blue, from the overall perspective of operating revenue, more than 85% of enterprises maintain the upward trend Among them, 125 enterprises have increased, and 21 enterprises have declined in operating income From the perspective of pharmaceutical industry segmentation, chemical pharmacy and Chinese patent medicine are still the "protagonists" of China's pharmaceutical market The overall growth trend of Chinese patent medicine industry is more than 10%; among many chemical pharmaceutical enterprises, especially some APIs In recent years, due to the increase of national environmental protection and strict supervision, many enterprises have stopped production or even closed down, resulting in the rise of API prices, but the overall industry net profit level is low; biopharmaceuticals account for a relatively small proportion, but the growth momentum is good, and the rise space is large This is mainly due to a series of national policies to encourage R & D innovation and the accumulation of talent technology experience 2017 is an accelerated year for the development of biomedical industry In January 2017, the national development and Reform Commission issued the 13th five year plan for the development of biological industry, focusing on the biological technology industry; in June 2017, the Ministry of science and Technology issued the 13th five year plan for scientific and technological innovation in the health industry, which clearly requires accelerating the clinical application of stem cells, regenerative medicine, immunotherapy and other biological treatment cutting-edge technologies 2018 is a key year for the pharmaceutical industry With the implementation of a series of policies such as provincial bidding and consistency evaluation in the new version of the medical insurance catalogue, the implementation will have a significant impact on the whole industry, while in the development process of the pharmaceutical industry, the research and development of biological innovative drugs will continue to be favored The industry believes that with the establishment of the state health insurance bureau and the introduction of deepening the VAT reform measures, it has a positive impact on some industries of traditional Chinese medicine At the same time, the industry insiders believe that as China's pharmaceutical industry enters a good and stable development period, the pharmaceutical equipment and pharmaceutical machinery industry related to it will also benefit, and also face higher technical equipment requirements In addition, the market development trend is the key that enterprises need to grasp At present, the existing pharmaceutical machinery manufacturers have made new development strategies for the spring breeze of national policies and the development trend of the industry For example, Shandong Tongzheng biomedical equipment design and Manufacturing Co., Ltd actively responds to the development strategy of "made in China 2025" by focusing on the three parts of biopharmaceutical equipment, API equipment and Chinese patent medicine equipment, firmly takes the road of technological innovation, equipment automation and intelligence, and works with customers to build a smart factory The author has learned that the pharmaceutical industry, especially in the field of biopharmaceutical industry, pays great attention to the process design and technical requirements of equipment Foreign pharmaceutical equipment enterprises attach great importance to modular design, application of isolation technology, equipment integration and other aspects However, the domestic equipment is still in its infancy, which needs to be studied, improved and upgraded.